CDKN2A and myxofibrosarcoma: The author proposed that the variation in growth rate and invasiveness may be partly explained by the presence of mutations in cell cycle checkpoint genes, such as CDKN2A, which is found to be mutated in approximately 16% of myxofibrosarcoma cases [29].